The overall goal of this Program Project is to develop a multicomponent vaccine for T.cruzi infection and define the optimal means and methods to distribute such a vaccine. During the previous grant period, a heavy emphasis was placed on putting together the infrastructure to test most T.cruzi genes for vaccine efficacy. That infrastructure is now well established and is functioning at high efficacy. The goals of Project 1: Gene Annotation and Cloning, is to keep the machine for gene identification and cloning running, to continue to fine-tune the process and to clone all T.cruzi genes of interest. We will rely on the Bioinformatic core and the T.cruzi Genome Sequencing Consortium (TcGSC) for gene identification and will also use the information derived from the proteomics studies described in Project 2 for identifying and prioritizing genes for cloning and testing. The primary criteria for selection of genes for cloning include: 1) presence in a relatively low number of alleles or variants in the genome, 2) expression in parasites stages that are present in the mammalian host, and 3) presence in the appropriate compartments to serve as effective targets for immune recognition. Genes identified as being as being of interest will be passed on to the Cloning Pipeline in which putative genes are cloned by means of automated primer design, and initial and secondary PCR reactions for the production of adapter sites required for cloning into Gateway entry vectors. Genes are then moved into vaccination vectors for testing in mice. We will clone and test a minimum of 1000 genes per year- and we predict that at this rate we can cover the majority of low copy genes in the T.cruzi genome. Genes will be tested in pools of approximately 96 for the ability to protect mice from lethal infection and protective pools will be further parsed to eventually determine the individual genes that provide the best protection. Genes cloned in this process will be used to produce and test protective cocktails of genes in the vaccination studies described in Project 3.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI044979-09
Application #
7193456
Study Section
Special Emphasis Panel (ZAI1-AWA-M (M1))
Program Officer
MO, Annie X Y
Project Start
1999-09-01
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
9
Fiscal Year
2007
Total Cost
$1,121,187
Indirect Cost
Name
University of Georgia
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
004315578
City
Athens
State
GA
Country
United States
Zip Code
30602
Castro Eiro, Melisa D; Alvarez, María G; Cooley, Gretchen et al. (2017) The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects. Front Immunol 8:1141
Weatherly, D Brent; Peng, Duo; Tarleton, Rick L (2016) Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi. BMC Genomics 17:729
Alvarez, María G; Bertocchi, Graciela L; Cooley, Gretchen et al. (2016) Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses. PLoS Negl Trop Dis 10:e0004657
Albareda, M Cecilia; Perez-Mazliah, Damián; Natale, M Ailén et al. (2015) Perturbed T cell IL-7 receptor signaling in chronic Chagas disease. J Immunol 194:3883-9
Bustamante, Juan M; Tarleton, Rick L (2014) Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol 7:317-25
Hartley, Ashley N; Cooley, Gretchen; Gwyn, Sarah et al. (2014) Frequency of IFN?-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection. Vet Res 45:6
Bustamante, Juan M; Craft, Julie M; Crowe, Byron D et al. (2014) New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis 209:150-62
Perez-Mazliah, D E; Alvarez, M G; Cooley, G et al. (2013) Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother 68:424-37
Argüello, Rafael J; Albareda, María C; Alvarez, María G et al. (2012) Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One 7:e35966
Minning, Todd A; Weatherly, D Brent; Flibotte, Stephane et al. (2011) Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics 12:139

Showing the most recent 10 out of 32 publications